Altimmune Inc
ALTHealthcare·Biotechnology·USA·Small·NASD·Nov 13 • 7:00 AM ET
1.63+0.02 (0.99%)
2026-11-13 13:01 CET
Market cap
$316.26M
Revenue, TTM
0.03 USD m
Net income, TTM
-104.35 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-0.73
Price
ALT against its 20, 50 and 200-day averagesPatternshover a marker to name it
74.8% under the 52-week high of 6.44 on 23 Jan 2026. 52-week low 1.59 on 13 Nov 2026. Last 15 sessions, 39.0% high to low
Volume 0.04× normal · the line is the 50-bar volume average
Setup. RS line 0
CANSLIM 4 of 6 — fails: 52-Week High/Low: 0-10% below High; Performance: Year +50%
VCP 3 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Minervini 0 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High; Performance: Year +50%
Zanger 0 of 5 — fails: RSI (14): Not Oversold (>50); Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 1 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 2 of 4 — fails: EPS Growth Next Year: High (>25%); Return on Equity: Over +15%
Quality 2 of 5 — fails: Return on Equity: Over +15%; Net Profit Margin: High (>20%) — not on the tape: P/E: Under 25
Value 2 of 4 — fails: Return on Equity: Over +15% — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 1 of 4 — fails: Float: Under 100M; 200-Day Simple Moving Average: Price above SMA200; Performance: Year +50%
Accumulation 2 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; Performance: Year Up
Relative Strength 1 of 3 — fails: Performance: Year +100%; 200-Day Simple Moving Average: Price above SMA200
Profile
ALT52-week range, 1% of the way up
1.596.44
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. Its lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.
| Index | RUT |
|---|---|
| Employees | 57 |
| IPO | Oct 06, 2005 |
| Beta | 0.16 |
| ATR, 14d | 0.14 |
| Rel volume | 0.04 |
| Short float | 22.94% |
| Insider own | 5.59% |
| Inst own | 71.30% |
Snapshot
6 groupsValuation
| Index | RUT |
|---|---|
| Market Cap | $316.26M |
| Enterprise Value | 86.15M |
| Income | -104.35M |
| Sales | 0.03M |
| Book / share | 2.28 |
| Cash / share | 1.36 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 57 |
| IPO | Oct 06, 2005 |
Ratios
| Price / earnings | - |
|---|---|
| Forward price / earnings | - |
| Price / earnings / growth | - |
| Price / sales | 10542.09 |
| Price / book | 0.71 |
| Price / cash | 1.19 |
| Price / free cash flow | - |
| Value / cash profit | - |
| Value / sales | 2871.76 |
| Quick Ratio | 26.77 |
| Current Ratio | 23.93 |
| Debt / equity | 0.08 |
| Long-term debt / equity | 0.08 |
| Options and short | Yes / Yes |
Earnings
| Earnings / share | -0.73 |
|---|---|
| Earnings next year | -0.64 |
| Earnings next quarter | -0.16 |
| Earnings this year | 40.60% |
| Earnings next year | -8.18% |
| Earnings growth, 5 years | 13.89% |
| Past earnings growth | 17.87% 12.17% |
| Past sales growth | - -65.33% |
| Earnings vs last year | 33.01% |
| Sales vs last year | 30.00% |
| Earnings vs last quarter | 27.56% |
| Sales vs last quarter | -100.00% |
| Earnings | Nov 12 BMO |
| Surprise | -13.21% - |
Ownership
| Insiders own | 5.59% |
|---|---|
| Insider trades | 0.14% |
| Institutions own | 71.30% |
| Institution trades | 33.14% |
| Return on assets | -29.23% |
| Return on equity | -33.17% |
| Return on capital | -21.81% |
| Gross Margin | 100.00% |
| Operating margin | -439503.85% |
| Profit Margin | -401361.54% |
| 20-day average | -20.45% |
| 50-day average | -37.05% |
| 200-day average | -48.03% |
Technical
| Shares out | 194.54M |
|---|---|
| Shares floating | 183.64M |
| Short / float | 22.94% |
| Short ratio | 10.59 |
| Short interest | 42.13M |
| 52-week high | 6.44 -74.8% |
| 52-week low | 1.59 +2.3% |
| Volatility | 10.17% 6.97% |
| Average range | 0.14 |
| Strength index | 25.28 |
| Market sensitivity | 0.16 |
| Relative volume | 0.04 |
| Avg Volume | 3.98M |
| Volume | 8,477 |
Performance
| Perf Week | -21.83% |
|---|---|
| Perf Month | -31.11% |
| Perf Quarter | -45.80% |
| Perf Half Y | -42.95% |
| Perf YTD | -54.96% |
| Perf Year | -59.95% |
| Perf 3Y | -33.36% |
| Perf 5Y | -85.37% |
| Perf 10Y | -98.45% |
| Recommendation | 1.30 |
| Target Price | 16.89 |
| Prev Close | 1.61 |
| Price | 1.63 |
| Change % | 0.99% |
Analyst ratings
latest 10 of 20| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Jun 22, 2026 | Initiated | Leerink Partners | Outperform | $10 | +515.0% |
| Apr 24, 2026 | Upgrade | Goldman | Sell → Neutral | $2.50 | +53.8% |
| Mar 18, 2026 | Initiated | Truist | Buy | $12 | +638.1% |
| Jan 28, 2026 | Initiated | Barclays | Overweight | $20 | +1,130.1% |
| Jul 10, 2025 | Resumed | Goldman | Sell | $1 | -38.5% |
| Feb 28, 2025 | Initiated | William Blair | Mkt Perform | ||
| Jan 08, 2025 | Initiated | Stifel | Buy | $18 | +1,007.1% |
| Nov 12, 2024 | Initiated | UBS | Buy | $26 | +1,499.1% |
| Apr 29, 2024 | Downgrade | Guggenheim | Buy → Neutral | ||
| Jan 24, 2024 | Initiated | Goldman | Neutral | $13 | +699.6% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| VKTX | Viking Therapeutics Inc | 3.54B |
| SGMT | Sagimet Biosciences Inc | 756.17M |
| IVA | Inventiva ADR | 932.49M |
| GPCR | Structure Therapeutics Inc ADR | 1.42B |
| MDGL | Madrigal Pharmaceuticals Inc | 9.91B |
| KLRA | Kailera Therapeutics Inc | 1.72B |
| GALT | Galectin Therapeutics Inc | 316.67M |
| MBX | MBX Biosciences Inc | 2.71B |
| MTVA | MetaVia Inc | 9.27M |
| AARD | Aardvark Therapeutics Inc | 33.26M |
Insider trading
latest 14 of 23| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| Arbet-Engels Christophe | Chief Medical Officer | Oct 01 '26 | Option Exercise | 0.00 | 37,500 | 0 | 37,500 | Oct 05 04:10 PM |
| WEAVER GREGORY L | Chief Financial Officer | Oct 01 '26 | Option Exercise | 0.00 | 14,475 | 0 | 54,306 | Oct 05 04:05 PM |
| Richardson Linda M | Chief Commercial Officer | Sep 16 '26 | Option Exercise | 0.00 | 24,000 | 0 | 24,000 | Sep 17 04:05 PM |
| Durso Jerome Benedict | President and CEO | Aug 13 '26 | Buy | 2.95 | 15,000 | 44,250 | 62,500 | Aug 13 04:05 PM |
| GILL JOHN | Director | Apr 06 '26 | Buy | 3.41 | 9,200 | 31,350 | 21,700 | Apr 06 04:05 PM |
| WEAVER GREGORY L | Chief Financial Officer | Apr 01 '26 | Buy | 3.15 | 10,000 | 31,499 | 38,078 | Apr 01 04:05 PM |
| Durso Jerome Benedict | President and CEO | Apr 01 '26 | Buy | 3.14 | 15,000 | 47,100 | 47,500 | Apr 01 04:05 PM |
| WEAVER GREGORY L | Chief Financial Officer | Mar 06 '26 | Buy | 3.54 | 5,000 | 17,700 | 28,078 | Mar 09 07:05 AM |
| Durso Jerome Benedict | President and CEO | Mar 06 '26 | Buy | 3.54 | 20,000 | 70,790 | 32,500 | Mar 09 07:00 AM |
| Roberts M Scot | Chief Scientific Officer | Feb 02 '26 | Option Exercise | 0.00 | 7,775 | 0 | 115,153 | Feb 03 04:15 PM |
| Roberts M Scot | Chief Scientific Officer | Jan 30 '26 | Option Exercise | 0.00 | 9,275 | 0 | 104,670 | Feb 03 04:15 PM |
| Garg Vipin K | Director | Jan 30 '26 | Option Exercise | 0.00 | 26,775 | 0 | 429,225 | Feb 02 04:15 PM |
| Jordt Raymond M | Chief Business Officer | Jan 27 '26 | Option Exercise | 0.00 | 15,850 | 0 | 69,765 | Jan 29 04:15 PM |
| Garg Vipin K | Director | Jan 27 '26 | Option Exercise | 0.00 | 41,200 | 0 | 420,348 | Jan 29 04:10 PM |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| VTI | Vanguard Morningstar Total Stock Market ETF | AUM: 696.31B |
| IWM | iShares Russell 2000 Index Fund | AUM: 77.86B |
| XBI | State Street SPDR S&P Biotech ETF | AUM: 10.59B |
| VXF | Vanguard Extended Market Index ETF | AUM: 30.79B |
| IWN | iShares Russell 2000 Value ETF | AUM: 14.17B |
| VTWO | Vanguard Russell 2000 Index ETF | AUM: 16.90B |
| FESM | Fidelity Enhanced Small Cap Core ETF | AUM: 6.90B |
| IBB | iShares Biotechnology ETF | AUM: 11.39B |
| VHT | Vanguard Health Care ETF | AUM: 21.54B |
| IWC | iShares Micro-Cap ETF | AUM: 1.23B |
News
latest 14 of 200- Why Did NVDA, ALT, PLUG Stocks Plunge To 52-Week Lows Today? (Stocktwits) -16.58%
- Altimmune Misses As Phase 3 Spending Ramps; Pipeline Advances, But Shares Sit Near A 52-Week Low (Earnings Whispers)
- Altimmune Announces Third Quarter 2026 Financial Results and Business Update (GlobeNewswire)
- Altimmune Announces Publication of IMPACT Phase 2b 48-Week Data in MASH in The Lancet Gastroenterology & Hepatology (GlobeNewswire)
- Altimmune Presents Positive Late-Breaking Pemvidutide Data at AASLD The Liver Meeting 2026 in Patients with Alcohol Use Disorder (GlobeNewswire)
- Altimmune's Sell-Off Puts Phase 3 Execution And AUD Funding Plans Under The Microscope (Earnings Whispers) +5.58%
- Altimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting 2026 (GlobeNewswire) -7.08%
- Altimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026 (GlobeNewswire)
- Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic Evolution (GlobeNewswire)
- Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting 2026 (GlobeNewswire)
- Altimmune to Participate in Stifel Cardiometabolic Forum (GlobeNewswire) -6.45%
- VKTX, GPCR, ALT Stocks Rise: Novo Nordisk Signals Bigger M&A As It Chases Over 5 Multi-Blockbusters (Stocktwits)
- Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference (GlobeNewswire)
- Altimmune Inc (ALT) (Q2 2026) Earnings Call Highlights: Advancing MASH and AUD Pipelines with ... (GuruFocus.com)
Quarterly earnings
2026Q3 EPS -0.150 missed -0.133, from -0.210 a year earlier. Sales 0.00 matched 0.00, from 0.01 a year earlier
The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.
| Period | Reported | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | Surprise | Year-ago quarter | Analysts | Next session |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026Q3ended 2026-09-30 | 2026-11-12 08:30 | -0.150 | -0.133 | -0.154 | 0.00 | 0.00 | EPS +13.2% · sales - | vs 2025Q3, year-ago quarter · EPS -28.6% · sales -100.0% | 10 EPS · 7 sales | Open -1.55% vs SPY -0.77%. Close -16.58% vs SPY -0.35% |
| 2026Q2ended 2026-06-30 | 2026-08-12 08:30 | -0.120 | -0.139 | -0.123 | 0.00 | 0.00 | EPS -13.4% · sales - | vs 2025Q2, year-ago quarter · EPS -55.6% · sales -100.0% | 10 EPS · 7 sales | Open +1.67% vs SPY +0.54%. Close -2.33% vs SPY +0.25% |
| 2026Q1ended 2026-03-31 | 2026-05-13 08:30 | -0.180 | -0.242 | -0.181 | 0.00 | 0.00 | EPS -25.7% · sales -100.0% | vs 2025Q1, year-ago quarter · EPS -30.8% · sales -100.0% | 9 EPS · 7 sales | Open -3.25% vs SPY +0.04%. Close -1.95% vs SPY +0.56% |
| 2025Q4ended 2025-12-31 | 2026-03-05 08:30 | -0.270 | -0.234 | -0.272 | 0.03 | 0.00 | EPS +15.4% · sales +4233.3% | vs 2024Q4, year-ago quarter · EPS -18.2% · sales +420.0% | 9 | Open -3.98% vs SPY -0.45%. Close -17.92% vs SPY -0.56% |
| 2025Q3ended 2025-09-30 | 2025-11-06 08:30 | -0.210 | -0.272 | -0.213 | 0.01 | 0.00 | EPS -22.8% · sales +257.1% | vs 2024Q3, year-ago quarter · EPS -34.4% · sales 0.0% | 9 EPS · 7 sales | Open +1.87% vs SPY -0.16%. Close +5.07% vs SPY -1.07% |
| 2025Q2ended 2025-06-30 | 2025-08-12 08:30 | -0.270 | -0.336 | -0.272 | 0.01 | 0.00 | EPS -19.7% · sales +257.1% | vs 2024Q2, year-ago quarter · EPS -22.9% · sales 0.0% | 10 EPS · 7 sales | Open +3.85% vs SPY +0.37%. Close +7.10% vs SPY +1.06% |
| 2025Q1ended 2025-03-31 | 2025-05-13 08:30 | -0.260 | -0.352 | -0.259 | 0.01 | 0.00 | EPS -26.1% · sales - | vs 2024Q1, year-ago quarter · EPS -23.5% · sales 0.0% | 9 EPS · 6 sales | Open +1.03% vs SPY +0.07%. Close -4.16% vs SPY +0.66% |
| 2024Q4ended 2024-12-31 | 2025-02-27 08:30 | -0.330 | -0.333 | -0.325 | 0.01 | 0.00 | EPS -0.8% · sales - | vs 2023Q4, year-ago quarter · EPS -38.9% · sales -86.5% | 8 EPS · 6 sales | Open +1.09% vs SPY +0.39%. Close +8.08% vs SPY -1.60% |
| 2024Q3ended 2024-09-30 | 2024-11-12 08:30 | -0.320 | -0.357 | -0.321 | 0.01 | 0.00 | EPS -10.3% · sales +614.3% | vs 2023Q3, year-ago quarter · EPS -17.9% · sales -98.6% | 8 EPS · 7 sales | Open +3.67% vs SPY -0.01%. Close +29.12% vs SPY -0.31% |
| 2024Q2ended 2024-06-30 | 2024-08-08 08:30 | -0.350 | -0.349 | -0.347 | 0.01 | 0.00 | EPS +0.4% · sales +614.3% | vs 2023Q2, year-ago quarter · EPS +9.4% · sales -16.7% | 7 | Open +5.45% vs SPY +1.01%. Close +15.09% vs SPY +2.31% |
| 2024Q1ended 2024-03-31 | 2024-05-09 08:30 | -0.340 | -0.370 | -0.345 | 0.01 | 0.00 | EPS -8.1% · sales - | vs 2023Q1, year-ago quarter · EPS -15.0% · sales -76.2% | 7 | Open +0.84% vs SPY +0.04%. Close +7.82% vs SPY +0.58% |
| 2023Q4ended 2023-12-31 | 2024-03-27 08:30 | -0.540 | -0.455 | -0.541 | 0.04 | 0.00 | EPS +18.7% · sales +1661.9% | vs 2022Q4, year-ago quarter · EPS +25.6% · sales -133.6% | 8 EPS · 7 sales | Open +7.75% vs SPY +0.56%. Close +2.77% vs SPY +0.84% |
| 2023Q3ended 2023-09-30 | 2023-11-07 08:30 | -0.390 | -0.453 | -0.385 | 0.36 | 0.00 | EPS -13.8% · sales +40122.2% | vs 2022Q3, year-ago quarter · EPS -18.7% · sales +18000.0% | 8 EPS · 7 sales | - |
| 2023Q2ended 2023-06-30 | 2023-08-10 08:30 | -0.320 | -0.465 | -0.317 | 0.01 | 0.00 | EPS -31.2% · sales +100.0% | vs 2022Q2, year-ago quarter · EPS -23.8% · sales -25.0% | 8 EPS · 7 sales | - |
| 2023Q1ended 2023-03-31 | 2023-05-11 08:30 | -0.400 | -0.480 | -0.401 | 0.02 | 0.00 | EPS -16.7% · sales - | vs 2022Q1, year-ago quarter · EPS -9.1% · sales -34.4% | 8 EPS · 7 sales | - |
| 2022Q4ended 2022-12-31 | 2023-02-28 08:30 | -0.430 | -0.501 | -0.433 | -0.11 | 0.03 | EPS -14.2% · sales -480.6% | vs 2021Q4, year-ago quarter · EPS -24.6% · sales -103.4% | 7 | - |
Annual earnings
2025FY EPS -1.000 missed -0.976, from -1.340 a year earlier. Sales 0.04 beat 0.01, from 0.02 a year earlier
Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.
earnings feed, not the snapshot. Not the statement ratio.
| Period | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | P/E, earnings feed |
|---|---|---|---|---|---|---|
| 2030FYestimate | - | -0.717 | - | - | 153.33 | - |
| 2029FYestimate | - | -0.673 | - | - | 34.20 | - |
| 2028FYestimate | - | -0.639 | - | - | 0.00 | - |
| 2027FYestimate | - | -0.643 | - | - | 0.00 | - |
| 2026FYestimate | - | -0.594 | - | - | 0.00 | - |
| 2025FY | -1.000 | -0.976 | -0.985 | 0.04 | 0.01 | - |
| 2024FY | -1.340 | -1.349 | -1.339 | 0.02 | 0.00 | - |
| 2023FY | -1.660 | -1.503 | -1.661 | 0.43 | 0.34 | - |
| 2022FY | -1.810 | -2.004 | -1.805 | -0.07 | 0.03 | - |
| 2021FY | -2.350 | -2.413 | -2.352 | 4.41 | 1.18 | - |
| 2020FY | -1.910 | -2.563 | -1.913 | 8.19 | 7.69 | - |
| 2019FY | -1.600 | -1.520 | -1.598 | 5.80 | 5.98 | - |
| 2018FY | -15.160 | - | -15.158 | 10.33 | - | - |
| 2017FY | -120.3 | -82.500 | -120.3 | 10.74 | 9.63 | - |
| 2016FY | 885 | - | -498 | 5.23 | - | 0.13 |
| 2015FY | -15.000 | - | - | 10.64 | - | - |
| 2014FY | -51.000 | - | -51.000 | 10.19 | - | - |
| 2013FY | -63.000 | -42.000 | -69.000 | 17.91 | 17.26 | - |
| 2012FY | -30.000 | -36.000 | -30.000 | 25.18 | 25.66 | - |
| 2011FY | -24.000 | -72.000 | -24.000 | 24.27 | 23.90 | - |
| 2010FY | -324 | -200 | -324 | 20.99 | 21.25 | - |
Quarterly results
2026Q3 revenue 0.00, from 0.01 a year earlier. 2025Q4 operating margin -96,300%, from -248,700% a year earlier
From the quarterly statement. Not an estimate.
Estimate revisions
Latest snapshot of each period and type. 2026FY E -0.59 per share.
| Period | Type | Scale | Date | Mean | vs prior date |
|---|---|---|---|---|---|
| 2026FY | E | per share | 2026-11-12 | -0.59 | +2.0% |
| 2026Q4 | E | per share | 2026-11-12 | -0.16 | +2.0% |
| 2026FY | R | per share | 2026-11-12 | -0.57 | +1.1% |
| 2026Q4 | R | per share | 2026-11-12 | -0.14 | +1.4% |
| 2026FY | S | per share | 2026-11-12 | 0.00 | - |
| 2026Q4 | S | per share | 2026-11-12 | 0.00 | - |
| 2026Q3 | E | per share | 2026-11-09 | -0.13 | -0.1% |
| 2026Q3 | R | per share | 2026-10-28 | -0.13 | 0.0% |
| 2026Q3 | S | per share | 2026-08-12 | 0.00 | - |
| 2026Q2 | E | per share | 2026-07-29 | -0.14 | 0.0% |
| 2026Q2 | R | per share | 2026-07-29 | -0.16 | 0.0% |
| 2026Q2 | S | per share | 2026-07-21 | 0.00 | -100.0% |
| 2026Q1 | E | per share | 2026-05-08 | -0.24 | +0.1% |
| 2026Q1 | S | per share | 2026-05-08 | 0.00 | +7.7% |
| 2026Q1 | R | per share | 2026-05-06 | -0.25 | -2.0% |
| 2025FY | E | per share | 2026-03-03 | -0.98 | 0.0% |
| 2025Q4 | E | per share | 2026-03-03 | -0.23 | 0.0% |
| 2025FY | S | per share | 2026-03-03 | 0.01 | 0.0% |
| 2025FY | R | per share | 2026-01-26 | -0.95 | +0.3% |
| 2025Q4 | R | per share | 2026-01-26 | -0.23 | -2.2% |
| 2025Q4 | S | per share | 2026-01-26 | 0.00 | 0.0% |
| 2025Q3 | E | per share | 2025-10-26 | -0.27 | 0.0% |
| 2025Q3 | R | per share | 2025-10-26 | -0.25 | 0.0% |
| 2025Q3 | S | per share | 2025-10-09 | 0.00 | -33.3% |
| 2025Q2 | E | per share | 2025-08-03 | -0.34 | 0.0% |
| 2025Q2 | S | per share | 2025-08-03 | 0.00 | 0.0% |
| 2025Q2 | R | per share | 2025-07-28 | -0.33 | 0.0% |
| 2025Q1 | E | per share | 2025-05-13 | -0.35 | 0.0% |
| 2025Q1 | R | per share | 2025-05-13 | -0.34 | 0.0% |
| 2025Q1 | S | per share | 2025-04-02 | 0.00 | - |
| 2024FY | S | per share | 2025-02-27 | 0.00 | - |
| 2024Q4 | S | per share | 2025-02-27 | 0.00 | - |
| 2024FY | R | per share | 2025-02-21 | -1.31 | +1.9% |
| 2024Q4 | R | per share | 2025-02-21 | -0.30 | +1.7% |
| 2024FY | E | per share | 2025-02-19 | -1.35 | -0.5% |
| 2024Q4 | E | per share | 2025-02-19 | -0.33 | -0.9% |
| 2024Q3 | E | per share | 2024-10-22 | -0.36 | 0.0% |
| 2024Q3 | R | per share | 2024-10-22 | -0.34 | -11.8% |
| 2024Q3 | S | per share | 2024-08-21 | 0.00 | +14.3% |
| 2024Q2 | E | per share | 2024-07-27 | -0.35 | 0.0% |
| 2024Q2 | R | per share | 2024-07-27 | -0.32 | 0.0% |
| 2024Q2 | S | per share | 2024-07-23 | 0.00 | 0.0% |
| 2024Q1 | E | per share | 2024-04-26 | -0.37 | -1.3% |
| 2024Q1 | S | per share | 2024-04-26 | 0.00 | - |
| 2024Q1 | R | per share | 2024-03-28 | -0.39 | +6.9% |
| 2023FY | E | per share | 2024-03-25 | -1.50 | +1.3% |
| 2023FY | S | per share | 2024-02-23 | 0.34 | -0.4% |
| 2023FY | R | per share | 2024-01-21 | -1.40 | 0.0% |
Estimate history
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | MRQ |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -120.3 | -15.158 | -1.598 | -1.913 | -2.352 | -1.805 | -1.661 | -1.339 | -1.00 | -0.7302 | - |
| Sales USD millions | 11 | 10 | 6 | 8 | 4 | 0 | 0 | 0 | 0 | 0 | - |
| Shares million shares | 1 | 9 | 15 | 37 | 41 | 49 | 71 | 72 | 111 | - | 195 |
| Metric | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.321 | -0.325 | -0.259 | -0.272 | -0.213 | -0.272 | -0.181 | -0.123 | -0.154 |
| Sales USD millions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shares million shares | 71 | 72 | 78 | 85 | 96 | 111 | 130 | 194 | 195 |
Income statement, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.03 | 0.04+100.0% | 0.02-95.3% | 0.43 | -0.07-101.6% | 4.41-46.2% | 8.19+41.2% | 5.80-43.9% | 10.33 |
| Cost of Goods Sold Incl. D&A | 0.00 | 0.11-54.2% | 0.24-50.0% | 0.48-4.0% | 0.50-9.1% | 0.55 | - | - | - |
| Gross Profit | 0.03 | -0.07 | -0.22 | -0.05 | -0.57-114.8% | 3.86 | - | - | - |
| Selling, General and Administrative Excl. Other | 114.22 | 94.42-8.3% | 102.95+23.4% | 83.46-4.2% | 87.09-2.5% | 89.30+92.4% | 46.42+106.8% | 22.45-19.6% | 27.92 |
| Research and Development | 80.20 | 66.32-19.1% | 81.99+25.5% | 65.32-6.6% | 69.95-6.0% | 74.42+122.4% | 33.46+135.8% | 14.19-22.8% | 18.38 |
| Other Operating Expense | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -114.27 | -94.49 | -103.17 | -83.51 | -87.65 | -85.44 | -38.53 | -17.03 | -17.89 |
| Interest Expense | 4.16 | 1.64+16300.0% | 0.01-75.0% | 0.04+300.0% | 0.010.0% | 0.010.0% | 0.01 | 0.00-100.0% | 0.30 |
| Unusual Expense | - | 0.00 | 0.00-100.0% | 12.42+13700.0% | 0.09-99.2% | 11.47-29.5% | 16.27+269.8% | 4.40-84.1% | 27.63 |
| Net Income Before Taxes | -104.35 | -88.77 | -95.06 | -88.45 | -84.91 | -97.09 | -54.46 | -20.58 | -45.32 |
| Income Taxes | 0.00 | -0.68 | 0.00 | 0.00 | -0.20 | 0.00 | -5.42 | -0.06 | -6.15 |
| Consolidated Net Income | -104.35 | -88.09 | -95.06 | -88.45 | -84.71 | -97.09 | -49.04 | -20.52 | -39.17 |
| Net Income From Continuing Operations | -104.35 | -88.09 | -95.06 | -88.45 | -84.71 | -97.09 | -49.04 | -20.52 | -39.17 |
| Net Income | -104.35 | -88.09 | -95.06 | -88.45 | -84.71 | -97.09 | -49.04 | -20.97 | -42.48 |
| EPS (Recurring) per share | -0.51 | -1.00 | -1.34 | -1.50 | -1.80 | -2.16 | -1.47 | -1.36 | -8.26 |
| EPS (Basic, Before Extraordinaries) per share | -0.73 | -1.00 | -1.34 | -1.66 | -1.81 | -2.35 | -1.91 | -1.60 | -15.16 |
| EPS (Diluted) per share | -0.73 | -1.00 | -1.34 | -1.66 | -1.81 | -2.35 | -1.91 | -1.60 | -15.16 |
| EBITDA | - | -94.38 | -102.93 | -83.03 | -87.15 | -84.89 | -38.24 | -16.65 | -17.59 |
| Non-Operating Income (Expense) | 14.88 | 7.35-9.5% | 8.12+8.0% | 7.52+164.8% | 2.84 | -0.17-148.6% | 0.35-59.3% | 0.86+72.0% | 0.50 |
| Other After Tax Adjustments | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | - | 12.70-11.7% | 14.39+35.2% | 10.64+66.3% | 6.40+15.9% | 5.52+193.6% | 1.88+104.3% | 0.92+50.8% | 0.61 |
| Price To Sales Ratio ratio | - | 7,757.46 | 25,596.73 | 1,406.17 | - | 85.74 | 35.33 | 4.28 | 0.56 |
| Gross Margin % | 100.00 | -173.17 | -1,090.00 | -11.97 | 835.29 | 87.50 | - | - | - |
| Operating Margin % | -439,503.85 | -230,460.98 | -515,860.00 | -19,603.29 | 128,902.94 | -1,937.35 | -470.78 | -293.63 | -173.20 |
| Net Margin % | -401,361.54 | -214,860.98 | -475,295.00 | -20,762.21 | 124,577.94 | -2,201.43 | -599.20 | -361.52 | -411.17 |
| Shares Outstanding million shares | 194.54 | 110.88+53.3% | 72.35+2.4% | 70.68+43.7% | 49.20+20.0% | 40.99+10.4% | 37.14+142.6% | 15.31+68.6% | 9.08 |
| Market Capitalization | 313.17 | 313.17+1204.3% | 24.01+0.8% | 23.81-25.3% | 31.86+122.2% | 14.34-2.4% | 14.70+1236.4% | 1.10-11.3% | 1.24 |
Income statement, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00-100.0% | 0.00-100.0% | 0.00-100.0% | 0.03+200.0% | 0.010.0% | 0.010.0% | 0.010.0% | 0.01-75.0% |
| Cost of Goods Sold Incl. D&A | 0.00-100.0% | 0.02-33.3% | 0.02-33.3% | 0.030.0% | 0.03-25.0% | 0.03-50.0% | 0.03-72.7% | 0.03-98.4% |
| Gross Profit | 0.00 | -0.02 | -0.02 | 0.00 | -0.02 | -0.03 | -0.02 | -0.03 |
| Selling, General and Administrative Excl. Other | 35.70+71.3% | 25.41+11.0% | 24.22+11.2% | 28.89+16.3% | 20.84-15.7% | 22.90-14.2% | 21.79-18.4% | 24.84+28.4% |
| Research and Development | 27.02+81.0% | 18.63+8.3% | 16.17+2.3% | 18.38-7.1% | 14.93-24.6% | 17.21-18.7% | 15.80-26.5% | 19.78+17.0% |
| Other Operating Expense | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -35.70 | -25.43 | -24.24 | -28.89 | -20.86 | -22.92 | -21.82 | -24.87 |
| Interest Expense | 1.12+128.6% | 1.10+323.1% | 1.07 | 0.88 | 0.49+4800.0% | 0.26 | 0.00 | 0.00 |
| Unusual Expense | - | 0.80 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% |
| Net Income Before Taxes | -31.61 | -22.82 | -22.56 | -27.36 | -19.01 | -22.15 | -20.26 | -23.18 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.68 | 0.00 |
| Consolidated Net Income | -31.61 | -22.82 | -22.56 | -27.36 | -19.01 | -22.15 | -19.57 | -23.18 |
| Net Income From Continuing Operations | -31.61 | -22.82 | -22.56 | -27.36 | -19.01 | -22.15 | -19.57 | -23.18 |
| Net Income | -31.61 | -22.82 | -22.56 | -27.36 | -19.01 | -22.15 | -19.57 | -23.18 |
| EPS (Recurring) per share | -0.15 | -0.12 | -0.18 | -0.27 | -0.21 | -0.27 | -0.26 | -0.33 |
| EPS (Basic, Before Extraordinaries) per share | -0.15 | -0.12 | -0.18 | -0.27 | -0.21 | -0.27 | -0.26 | -0.33 |
| EPS (Diluted) per share | -0.15 | -0.12 | -0.18 | -0.27 | -0.21 | -0.27 | -0.26 | -0.33 |
| EBITDA | - | -25.41 | -24.22 | -28.87 | -20.83 | -22.89 | -21.79 | -24.83 |
| Non-Operating Income (Expense) | 5.22+123.1% | 4.50+332.7% | 2.75+76.3% | 2.41+42.6% | 2.34+21.2% | 1.04-50.7% | 1.56-35.0% | 1.69-14.6% |
| Other After Tax Adjustments | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | - | 2.79-1.1% | 3.38+6.6% | 3.90+16.4% | 3.55+15.3% | 2.82-34.6% | 3.17-13.2% | 3.35+35.6% |
| Price To Sales Ratio ratio | - | 18,185.45 | 10,648.40 | 8,858.89 | 16,855.30 | 15,765.91 | 18,886.94 | 25,689.55 |
| Gross Margin % | - | - | - | 0.00 | -440.00 | -500.00 | -480.00 | -560.00 |
| Operating Margin % | - | - | - | -111,126.92 | -417,180.00 | -458,440.00 | -436,300.00 | -497,320.00 |
| Net Margin % | - | - | - | -105,223.08 | -380,280.00 | -442,920.00 | -391,500.00 | -463,600.00 |
| Shares Outstanding million shares | 194.54+103.5% | 194.47+128.6% | 130.22+67.3% | 110.88+53.3% | 95.60+34.4% | 85.08+19.7% | 77.83+9.8% | 72.35+2.4% |
| Market Capitalization | 313.17+2251.1% | 591.20+3307.5% | 400.62+2050.4% | 376.67+1468.8% | 13.32-29.0% | 17.35-17.3% | 18.63-13.5% | 24.01+0.8% |
Balance sheet, annual
| Metric | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 | 2017FY12/31/2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 273.50+107.3% | 131.93-33.3% | 197.86+7.0% | 184.91-2.8% | 190.33-11.9% | 215.96+479.4% | 37.27+8.5% | 34.35+179.3% | 12.30 |
| Short Term Receivables | 1.74-44.2% | 3.12-35.7% | 4.85+90.9% | 2.54-56.5% | 5.84-52.8% | 12.37+649.7% | 1.65-63.1% | 4.47-56.0% | 10.17 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 2.76+31.4% | 2.10-69.2% | 6.82+27.2% | 5.36-32.6% | 7.95+311.9% | 1.93+310.6% | 0.47-14.5% | 0.55-44.4% | 0.99 |
| Total Current Assets | 277.99+102.7% | 137.15-34.5% | 209.53+8.7% | 192.81-5.5% | 204.13-11.3% | 230.26+484.6% | 39.39+0.1% | 39.37+67.7% | 23.47 |
| Net Property, Plant & Equipment | 1.74-15.1% | 2.05+103.0% | 1.01-39.9% | 1.68-25.3% | 2.25+14.8% | 1.96+8.9% | 1.80+34.3% | 1.34+123.3% | 0.60 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 0.00 | 0.00 | 0.00-100.0% | 12.420.0% | 12.42-3.1% | 12.82+0.7% | 12.73-8.1% | 13.85-64.2% | 38.72 |
| Other Assets | 0.20+100.0% | 0.100.0% | 0.10+400.0% | 0.02-71.4% | 0.070.0% | 0.07-46.2% | 0.13-27.8% | 0.18-25.0% | 0.24 |
| Total Assets | 279.93+100.9% | 139.31-33.9% | 210.64+1.8% | 206.93-5.5% | 218.86-10.7% | 245.12+353.4% | 54.06-1.3% | 54.75-13.1% | 63.03 |
| Short Term Debt Incl. Current Port. of LT Debt | 0.26-7.1% | 0.28-44.0% | 0.50+11.1% | 0.45+9.8% | 0.41+13.9% | 0.36+38.5% | 0.26+271.4% | 0.07+40.0% | 0.05 |
| Accounts Payable | 2.72+1195.2% | 0.21-89.9% | 2.07-56.9% | 4.80+136.5% | 2.03+232.8% | 0.61+2950.0% | 0.02-94.6% | 0.37+184.6% | 0.13 |
| Income Tax Payable | - | - | 0.00-100.0% | 1.17 | - | - | - | - | - |
| Other Current Liabilities | 12.02+20.4% | 9.98+4.2% | 9.58-9.9% | 10.63-32.8% | 15.83+43.3% | 11.05+202.7% | 3.65-10.5% | 4.08+11.5% | 3.66 |
| Total Current Liabilities | 15.00+43.3% | 10.47-13.8% | 12.14-28.8% | 17.05-6.7% | 18.28+52.1% | 12.02+206.6% | 3.92-13.5% | 4.53+18.0% | 3.84 |
| Long Term Debt | 35.43+2430.7% | 1.40+723.5% | 0.17-74.6% | 0.67-40.2% | 1.12-23.8% | 1.47-0.7% | 1.48+196.0% | 0.50 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | - | - | - | - | - | - | - | 0.06-99.0% | 5.94 |
| Other Liabilities | 4.61+17.3% | 3.93-6.9% | 4.22+7.9% | 3.91+1084.8% | 0.33-94.3% | 5.75+83.7% | 3.13+131.9% | 1.35-70.5% | 4.57 |
| Total Liabilities | 55.04+248.4% | 15.80-4.5% | 16.54-23.6% | 21.64+9.7% | 19.73+2.5% | 19.24+125.3% | 8.54+32.6% | 6.44-55.1% | 14.35 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 9.28 |
| Common Equity | 224.89+82.1% | 123.51-36.4% | 194.10+4.8% | 185.29-7.0% | 199.13-11.8% | 225.88+396.2% | 45.52-5.8% | 48.31+22.6% | 39.40 |
| Total Shareholders Equity | 224.89+82.1% | 123.51-36.4% | 194.10+4.8% | 185.29-7.0% | 199.13-11.8% | 225.88+396.2% | 45.52-5.8% | 48.31-0.8% | 48.68 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 224.89+82.1% | 123.51-36.4% | 194.10+4.8% | 185.29-7.0% | 199.13-11.8% | 225.88+396.2% | 45.52-5.8% | 48.31-0.8% | 48.68 |
| Total Liabilities & Stockholders Equity | 279.93+100.9% | 139.31-33.9% | 210.64+1.8% | 206.93-5.5% | 218.86-10.7% | 245.12+353.4% | 54.06-1.3% | 54.75-13.1% | 63.03 |
| Book Value Per Share per share | 2.03+18.7% | 1.71-37.8% | 2.75-27.1% | 3.77-22.4% | 4.86-20.1% | 6.08+104.7% | 2.97-44.2% | 5.32-91.9% | 65.28 |
| Tangible Book Value Per Share per share | 2.03+18.7% | 1.71-37.8% | 2.75-21.7% | 3.51-22.9% | 4.55-20.7% | 5.74+168.2% | 2.14-43.7% | 3.80+239.3% | 1.12 |
| Full-Time Employees people | 57-3.4% | 590.0% | 59+13.5% | 52+10.6% | 47+9.3% | 43+72.0% | 25-7.4% | 27-10.0% | 30 |
| Price to Book Ratio ratio | 0.66 | 0.18 | 0.16 | 0.16 | 0.07 | 0.07 | 0.02 | 0.01 | 0.03 |
| Return on Assets % | -42.03 | -54.33 | -42.36 | -39.79 | -41.85 | -32.79 | -37.72 | -66.52 | -32.27 |
| Return on Equity % | -50.57 | -59.86 | -46.63 | -44.07 | -45.69 | -36.14 | -43.74 | -80.77 | -136.27 |
| Return on Invested Capital % | -33.84 | -76.10 | -45.53 | -45.55 | -48.48 | -21.57 | -43.66 | -80.25 | -95.37 |
| Quick Ratio ratio | 18.54 | 13.10 | 17.25 | 11.31 | 11.17 | 19.16 | 10.04 | 8.70 | 6.11 |
| Current Ratio ratio | 18.54 | 13.10 | 17.25 | 11.31 | 11.17 | 19.16 | 10.04 | 8.70 | 6.11 |
Cash flow, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | - | -88.09 | -95.06 | -88.45 | -84.71 | -97.09 | -49.04 | -20.52 | -39.17 |
| Depreciation | - | 0.11-54.2% | 0.24-50.0% | 0.48 | -0.20-136.4% | 0.55+83.3% | 0.30-23.1% | 0.39+30.0% | 0.30 |
| Deferred Taxes & Investment Tax Credit | - | -0.68 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.06 | -6.15 |
| Other Funds (Non Cash) | - | 14.38+37.1% | 10.49-48.2% | 20.24+146.2% | 8.22-55.4% | 18.43-2.1% | 18.82+114.6% | 8.77-69.4% | 28.65 |
| Funds from Operations | - | -74.29 | -84.33 | -67.73 | -76.70 | -78.11 | -29.92 | -11.42 | -16.37 |
| Extraordinary Item | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | - | 6.75+50.7% | 4.48 | -8.27-158.6% | 14.11 | -0.25 | -4.51-347.8% | 1.82-73.9% | 6.98 |
| Cash from Operating Activities | - | -67.53 | -79.85 | -76.00 | -62.59 | -78.36 | -34.44 | -9.60 | -9.39 |
| Capital Expenditures | - | -0.01 | 0.00 | -0.05 | -0.13 | -12.31 | -0.34 | -0.03 | -1.02 |
| Net Assets From Acquisitions | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 0.01 |
| Purchase or Sale of Investments | - | -132.46 | -28.39-306.0% | 13.78 | -73.27-173.4% | 99.83 | -71.75 | -28.26 | 0.00 |
| Purchase of Investments | - | -285.45 | -115.73 | -88.63 | -73.27 | -7.59 | -128.16 | -28.26 | 0.00 |
| Sale Or Maturity of Investments | - | 152.99+75.2% | 87.34-14.7% | 102.41 | 0.00-100.0% | 107.43+90.4% | 56.41 | 0.00 | 0.00 |
| Other Uses | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Cash from Investing Activities | - | -132.47 | -28.39-306.8% | 13.73 | -73.40-183.9% | 87.52 | -72.09 | -28.29 | -1.00 |
| Cash Dividends Paid | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - |
| Change in Capital Stock | - | 173.63+1494.4% | 10.89-87.5% | 86.93+53.1% | 56.78-12.9% | 65.22-69.5% | 213.49+1581.0% | 12.70-63.8% | 35.04 |
| Repurchase of Common Pref Stock | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2.39 |
| Sale of Common Pref Stock | - | 173.63+1494.4% | 10.89-87.5% | 86.93+53.1% | 56.78-12.9% | 65.22-69.5% | 213.49+1581.0% | 12.70-66.1% | 37.43 |
| Proceedsfrom Stock Options | - | 173.29+1634.6% | 9.99-88.5% | 86.60+54.2% | 56.17-13.3% | 64.82-62.4% | 172.18+1259.0% | 12.67-66.1% | 37.40 |
| Issuance or Reduction of Debt, Net | - | 33.92 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.29 | -1.55 |
| Change in Long Term Debt | - | 33.92 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.55 |
| Issuance of Long Term Debt | - | 33.92 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.55 |
| Net Financing Active Other Cash Flow | - | -0.71 | -0.85 | -0.63 | 0.00 | 0.00 | 0.00-100.0% | 0.12 | -1.00 |
| Other Financing Activities Uses | - | -0.71 | -0.85 | -0.63 | 0.00 | 0.00 | 0.00 | -0.03 | -1.10 |
| Cash from Financing Activities | - | 206.84+1960.2% | 10.04-88.4% | 86.30+52.0% | 56.78-12.9% | 65.22-69.5% | 213.49+1603.8% | 12.53-61.4% | 32.49 |
| Exchange Rate Effect | - | - | - | - | - | - | - | 0.00 | -0.05 |
| Net Change in Cash | - | 6.83 | -98.19-508.6% | 24.03 | -79.20-206.5% | 74.38-30.5% | 106.96 | -25.36-215.0% | 22.05 |
| Free Cash Flow | - | -67.55 | -79.85 | -76.05 | -62.71 | -90.47 | -34.64 | -9.60 | -10.36 |
Balance sheet, quarterly
| Metric | 2026Q39/30/2026 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 265.10+25.7% | 326.32+78.2% | 331.58+121.2% | 273.50+107.3% | 210.82+51.2% | 183.15+11.0% | 149.87-17.7% | 131.93-33.3% |
| Short Term Receivables | 3.66+163.3% | 3.34+279.5% | 1.67-32.1% | 1.74-44.2% | 1.39-58.4% | 0.88-70.8% | 2.46-4.7% | 3.12-35.7% |
| Inventories | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 7.01+63.0% | 4.95+17.9% | 1.23-53.2% | 2.76+31.4% | 4.30+43.3% | 4.20+30.0% | 2.63-8.4% | 2.10-69.2% |
| Total Current Assets | 275.77+27.4% | 334.62+77.8% | 334.48+115.8% | 277.99+102.7% | 216.51+48.5% | 188.22+9.9% | 154.96-17.4% | 137.15-34.5% |
| Net Property, Plant & Equipment | 0.11-67.6% | 0.06-83.3% | 0.21-44.7% | 1.74-15.1% | 0.34-24.4% | 0.36-25.0% | 0.38-29.6% | 2.05+103.0% |
| Total Investments and Advances | 214.82 | 192.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | - | - | - | 0.00 | - | - | - | 0.00 |
| Other Assets | 4.94+210.7% | 0.29-83.5% | 0.95-50.5% | 0.20+100.0% | 1.59-4.2% | 1.76+4.8% | 1.92+540.0% | 0.100.0% |
| Total Assets | 495.65+126.9% | 527.21+177.0% | 335.63+113.4% | 279.93+100.9% | 218.45+47.7% | 190.35+9.8% | 157.26-16.5% | 139.31-33.9% |
| Short Term Debt Incl. Current Port. of LT Debt | - | 0.27+12.5% | 0.27+12.5% | 0.26-7.1% | 0.25-19.4% | 0.24-29.4% | 0.24-52.9% | 0.28-44.0% |
| Accounts Payable | 0.77-84.0% | 1.27+49.4% | 1.53+41.7% | 2.72+1195.2% | 4.80+324.8% | 0.85-68.4% | 1.08-71.3% | 0.21-89.9% |
| Other Current Liabilities | 10.76+42.5% | 10.96+34.8% | 9.53+12.4% | 12.02+20.4% | 7.55+5.0% | 8.13-32.9% | 8.48+19.9% | 9.98+4.2% |
| Total Current Liabilities | 11.53-8.6% | 12.50+35.6% | 11.32+15.5% | 15.00+43.3% | 12.61+45.9% | 9.22-39.1% | 9.80-13.5% | 10.47-13.8% |
| Long Term Debt | 34.99+123.4% | 35.75+129.0% | 35.58+2555.2% | 35.43+2430.7% | 15.66+972.6% | 15.61+927.0% | 1.34+3250.0% | 1.40+723.5% |
| Provision for Risks Charges | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 5.57+21.6% | 4.76+14.7% | 4.74+19.7% | 4.61+17.3% | 4.58+4.3% | 4.15+0.2% | 3.96-2.0% | 3.93-6.9% |
| Total Liabilities | 52.08+58.5% | 53.00+82.9% | 51.64+242.0% | 55.04+248.4% | 32.85+126.7% | 28.98+39.2% | 15.10-2.1% | 15.80-4.5% |
| Non-Equity Reserves | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 443.57+139.0% | 474.21+193.9% | 283.99+99.8% | 224.89+82.1% | 185.60+39.2% | 161.37+5.8% | 142.16-17.8% | 123.51-36.4% |
| Total Shareholders Equity | 443.57+139.0% | 474.21+193.9% | 283.99+99.8% | 224.89+82.1% | 185.60+39.2% | 161.37+5.8% | 142.16-17.8% | 123.51-36.4% |
| Accumulated Minority Interest | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 443.57+139.0% | 474.21+193.9% | 283.99+99.8% | 224.89+82.1% | 185.60+39.2% | 161.37+5.8% | 142.16-17.8% | 123.51-36.4% |
| Total Liabilities & Stockholders Equity | 495.65+126.9% | 527.21+177.0% | 335.63+113.4% | 279.93+100.9% | 218.45+47.7% | 190.35+9.8% | 157.26-16.5% | 139.31-33.9% |
| Book Value Per Share per share | 2.28+17.5% | 2.44+28.4% | 2.18+19.1% | 2.03+18.7% | 1.94+3.2% | 1.90-11.6% | 1.83-25.0% | 1.71-37.8% |
| Tangible Book Value Per Share per share | 2.28+17.5% | 2.44+28.4% | 2.18+19.1% | 2.03+18.7% | 1.94+3.2% | 1.90-11.6% | 1.83-25.0% | 1.71-37.8% |
| Full-Time Employees people | - | - | - | 57-3.4% | - | - | - | 590.0% |
| Price to Book Ratio ratio | 0.66 | 1.39 | 1.52 | 1.86 | 0.08 | 0.12 | 0.15 | 0.18 |
| Return on Assets % | -29.23 | -25.58 | -36.96 | -42.03 | -45.82 | -48.25 | -52.22 | -54.33 |
| Return on Equity % | -33.17 | -28.87 | -42.75 | -50.57 | -52.61 | -55.91 | -57.28 | -59.86 |
| Return on Invested Capital % | -6.60 | -4.48 | -7.06 | -10.51 | -9.45 | -12.51 | -13.64 | -18.56 |
| Quick Ratio ratio | - | 26.77 | 29.54 | 18.54 | 17.18 | 20.41 | 15.82 | 13.10 |
| Current Ratio ratio | 23.93 | 26.77 | 29.54 | 18.54 | 17.18 | 20.41 | 15.82 | 13.10 |
Cash flow, quarterly
| Metric | 2026Q3 | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 |
|---|---|---|---|---|---|---|---|---|
| Net Income | - | -22.82 | -22.56 | -27.36 | -19.01 | -22.15 | -19.57 | -23.18 |
| Depreciation | - | 0.02-33.3% | 0.02-33.3% | 0.030.0% | 0.03-25.0% | 0.03-50.0% | 0.03-72.7% | 0.03-98.4% |
| Other Funds (Non Cash) | - | 2.85-3.1% | 3.59+8.5% | 4.56+88.4% | 3.56+70.3% | 2.94-11.2% | 3.31+24.0% | 2.42-80.5% |
| Funds from Operations | - | -19.96 | -18.95 | -22.77 | -15.43 | -19.18 | -16.91 | -20.73 |
| Extraordinary Item | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | - | -4.26 | -1.99-2942.9% | 3.62+47.2% | 3.53 | -0.47-114.9% | 0.07-98.7% | 2.46+200.0% |
| Cash from Operating Activities | - | -24.22 | -20.94 | -19.15 | -11.90 | -19.65 | -16.84 | -18.27 |
| Capital Expenditures | - | -0.03 | -0.02 | -0.00 | 0.00 | -0.01 | 0.00 | 0.00 |
| Net Assets From Acquisitions | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | - | -221.41-319.0% | -3.67 | -79.16-680.8% | -149.32-12543.3% | 101.12 | -5.10 | 13.63 |
| Purchase of Investments | - | -289.07 | -43.29 | -88.55 | -149.32 | -4.43 | -43.14 | -13.21 |
| Sale Or Maturity of Investments | - | 67.66-35.9% | 39.62+4.2% | 9.40-65.0% | 0.00-100.0% | 105.55+441.3% | 38.04+171.7% | 26.84+3.7% |
| Other Uses | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | - | -221.44-319.0% | -3.69 | -79.16-680.8% | -149.32-12543.3% | 101.11 | -5.10 | 13.63 |
| Cash Dividends Paid | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | - | 210.88+455.7% | 79.17+127.5% | 61.21+506.6% | 39.67+14592.6% | 37.95+18875.0% | 34.80+10135.3% | 10.09-86.1% |
| Repurchase of Common Pref Stock | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | - | 210.88+455.7% | 79.17+127.5% | 61.21+506.6% | 39.67+14592.6% | 37.95+18875.0% | 34.80+10135.3% | 10.09-86.1% |
| Proceedsfrom Stock Options | - | 0.00-100.0% | 8.65-75.0% | 61.21+512.7% | 39.52 | 37.95 | 34.62 | 9.99-86.3% |
| Issuance or Reduction of Debt, Net | - | 0.00-100.0% | 0.00 | 19.65 | -0.32 | 14.60 | 0.00 | 0.00 |
| Change in Long Term Debt | - | 0.00-100.0% | 0.00 | 19.65 | -0.32 | 14.60 | 0.00 | 0.00 |
| Issuance of Long Term Debt | - | 0.00-100.0% | 0.00 | 19.65 | -0.32 | 14.60 | 0.00 | 0.00 |
| Reduction of Long Term Debt | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | - | 0.19 | -0.69 | -0.03 | 0.00 | -0.01 | -0.68 | -0.00 |
| Other Financing Activities Uses | - | 0.19 | -0.69 | -0.03 | 0.00 | -0.01 | -0.68 | -0.00 |
| Cash from Financing Activities | - | 211.07+301.7% | 78.47+130.0% | 80.83+701.1% | 39.35+14474.1% | 52.54 | 34.12 | 10.09-86.1% |
| Net Change in Cash | - | -34.59-125.8% | 53.84+342.0% | -17.48-420.7% | -121.87 | 134.00 | 12.18 | 5.45-88.7% |
| Free Cash Flow | - | -24.25 | -20.96 | -19.15 | -11.90 | -19.66 | -16.84 | -18.27 |
Revenue breakdown
USD millions, so a column adds up to the income statement. Share is of the latest year in that split. The change is versus the older year shown, not TTM.
| Name | 2024 | 2025 | vs 2024 | 2025 share |
|---|---|---|---|---|
| Total Pharmaceutical Preparations revenue | 0.02 | 0.04 | +105.0% | 100.0% |
| Total | 0.02 | 0.04 | +105.0% | 100.0% |
| Name | 2024 | 2025 | vs 2024 | 2025 share |
|---|---|---|---|---|
| United States | 0.02 | 0.04 | +105.0% | 100.0% |
| Total | 0.02 | 0.04 | +105.0% | 100.0% |
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 22.94% | 42.1M | 183.6M | 4.04M |
| 2026-10-15 | 23.00% | 42.2M | 183.6M | 4.24M |
| 2026-09-30 | 25.09% | 46.1M | 183.7M | 4.21M |
| 2026-09-15 | 28.17% | 51.7M | 183.7M | 4.45M |
| 2026-08-31 | 27.06% | 49.7M | 183.7M | 4.36M |
| 2026-08-14 | 27.75% | 51.0M | 183.7M | 4.11M |
| 2026-07-31 | 28.28% | 51.9M | 183.7M | 3.94M |
| 2026-07-15 | 26.27% | 48.2M | 183.7M | 4.41M |
| 2026-06-30 | 25.93% | 47.6M | 183.7M | 4.11M |
| 2026-06-15 | 22.83% | 41.9M | 183.7M | 3.78M |
| 2026-05-29 | 21.30% | 39.1M | 183.7M | 3.95M |
| 2026-05-15 | 20.49% | 37.6M | 183.7M | 3.96M |
| 2026-04-30 | 19.89% | 35.4M | 178.2M | 3.97M |
| 2026-04-15 | 22.23% | 28.7M | 129.3M | 3.87M |
| 2026-03-31 | 22.65% | 29.2M | 129.1M | 4.56M |
| 2026-03-13 | 20.51% | 26.5M | 129.1M | 4.87M |
| 2026-02-27 | 19.75% | 25.5M | 129.1M | 4.82M |
| 2026-02-13 | 20.22% | 25.1M | 124.3M | 4.91M |
| 2026-01-30 | 23.36% | 24.2M | 103.5M | 4.87M |
| 2026-01-15 | 25.49% | 26.4M | 103.6M | 4.13M |
Option chain
expiry 2026-11-13| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| call | 0.50 | 0.95 | 1.30 | 1.21 | 0.000 | 24.00 | 10.00 | 0.952 | -0.096 | 0.000 |
| call | 1.00 | 0.55 | 0.75 | 0.64 | 15.375 | 53.00 | 17.00 | 0.892 | -0.086 | 0.000 |
| call | 1.50 | 0.10 | 0.25 | 0.26 | 6.434 | 144 | 100 | 0.687 | -0.061 | 0.000 |
| call | 2.00 | 0.00 | 0.05 | 0.01 | 5.337 | 320 | 92.00 | 0.235 | -0.076 | 0.000 |
| call | 2.50 | 0.00 | 0.05 | 0.04 | 3.759 | 1.00 | 0.00 | 0.198 | -0.039 | 0.000 |
| call | 3.00 | 0.00 | 0.05 | 0.03 | 10.194 | 17.00 | 67.00 | 0.150 | -0.110 | 0.000 |
| call | 3.50 | 0.00 | 2.15 | 0.00 | 11.790 | 0.00 | 0.00 | 0.136 | -0.119 | 0.000 |
| call | 4.00 | 0.00 | 2.15 | 0.05 | 13.111 | 10.00 | 0.00 | 0.127 | -0.126 | 0.000 |
| call | 5.00 | 0.00 | 2.15 | 0.00 | 15.190 | 0.00 | 0.00 | 0.115 | -0.136 | 0.000 |
| put | 0.50 | 0.00 | 0.05 | 0.00 | 15.507 | 0.00 | 0.00 | -0.037 | -0.047 | 0.000 |
| put | 1.00 | 0.00 | 0.05 | 0.00 | 8.242 | 0.00 | 0.00 | -0.077 | -0.045 | 0.000 |
| put | 1.50 | 0.00 | 0.05 | 0.05 | 6.149 | 1.00 | 0.00 | -0.249 | -0.091 | 0.000 |
| put | 2.00 | 0.10 | 0.80 | 0.35 | 17.559 | 14.00 | 2.00 | -0.765 | -0.075 | 0.000 |
| put | 2.50 | 0.50 | 3.00 | 0.65 | 34.856 | 4.00 | 4.00 | -0.825 | -0.097 | 0.000 |
| put | 3.00 | 1.05 | 1.70 | 1.33 | 20.147 | 26.00 | 74.00 | -0.850 | -0.110 | 0.000 |
| put | 3.50 | 1.55 | 2.35 | 1.83 | 26.988 | 0.00 | 2.00 | -0.864 | -0.119 | 0.000 |
| put | 4.00 | 2.05 | 3.10 | 2.36 | 36.920 | 0.00 | 5.00 | -0.873 | -0.126 | 0.000 |
| put | 5.00 | 3.00 | 4.00 | 3.35 | 35.982 | 0.00 | 6.00 | -0.885 | -0.136 | 0.000 |
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-12 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-09-30 | SEC |
| 2026-11-12 | 8-K | Current report | 2026-11-12 | SEC |
| 2026-11-10 | SCHEDULE 13G | SEC | ||
| 2026-11-04 | 4 | Statement of changes in beneficial ownership of securities | 2026-11-02 | SEC |
| 2026-11-04 | 3 | Initial statement of beneficial ownership of securities | 2026-11-02 | SEC |
| 2026-11-04 | 4 | Statement of changes in beneficial ownership of securities | 2026-11-02 | SEC |
| 2026-11-04 | 3 | Initial statement of beneficial ownership of securities | 2026-11-02 | SEC |
| 2026-10-29 | 8-K | Current report | 2026-10-27 | SEC |
| 2026-10-27 | 8-K | Current report | 2026-10-23 | SEC |
| 2026-10-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-10-01 | SEC |
| 2026-10-05 | 4 | Statement of changes in beneficial ownership of securities | 2026-10-01 | SEC |
| 2026-10-02 | 4 | Statement of changes in beneficial ownership of securities | 2026-10-01 | SEC |
| 2026-10-02 | 3 | Initial statement of beneficial ownership of securities | 2026-10-01 | SEC |
| 2026-09-29 | 8-K | Current report | 2026-09-24 | SEC |
| 2026-09-17 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-16 | SEC |
| 2026-08-13 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-13 | SEC |
| 2026-08-12 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-08-12 | 8-K | Current report | 2026-08-12 | SEC |
| 2026-08-03 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-31 | SEC |
| 2026-08-03 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-31 | SEC |
| 2026-07-28 | 8-K | Current report | 2026-07-28 | SEC |
| 2026-06-16 | 8-K | Current report | 2026-06-16 | SEC |
| 2026-05-15 | SCHEDULE 13G/A | SEC | ||
| 2026-05-13 | S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans | SEC | |
| 2026-05-13 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-03-31 | SEC |
| 2026-05-13 | 8-K | Current report | 2026-05-13 | SEC |
| 2026-05-12 | SCHEDULE 13G | SEC | ||
| 2026-05-01 | 4 | Statement of changes in beneficial ownership of securities | 2026-05-01 | SEC |
| 2026-05-01 | 4 | Statement of changes in beneficial ownership of securities | 2026-05-01 | SEC |
| 2026-05-01 | 4 | Statement of changes in beneficial ownership of securities | 2026-05-01 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 44.25K | 1 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 109.95K | 3 | 0 | 0 |
| 2026-03 | 88.49K | 2 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 20.41K | 1 | 0 | 0 |
| 2025-12 | 104.82K | 3 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| BlackRock, Inc. | 10.48% |
| Deep Track Capital, LP | 9.90% |
| TCG Crossover Management, LLC | 5.14% |
| STATE STREET CORP | 4.30% |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.21% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 3.77% |
| MARSHALL WACE, LLP | 3.52% |
| VIKING GLOBAL INVESTORS LP | 3.45% |
| RA CAPITAL MANAGEMENT, L.P. | 3.34% |
| GEODE CAPITAL MANAGEMENT, LLC | 2.51% |
Funds
| Fund | % owned |
|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 4.16% |
| VANGUARD TOTAL STOCK MARKET INDEX FUND | 2.96% |
| iShares Russell 2000 ETF | 2.65% |
| Nuveen Quant Small Cap Equity Fund | 1.45% |
| VANGUARD STRATEGIC EQUITY FUND | 1.30% |
| VANGUARD EXTENDED MARKET INDEX FUND | 1.15% |
| Fidelity Small Cap Index Fund | 1.12% |
| iShares Russell 2000 Value ETF | 0.96% |
| BlackRock Advantage Small Cap Core Fund | 0.70% |
| iShares Biotechnology ETF | 0.67% |
OakChart. ALT. Cached 15 minutes. Terms